Lebbé C, Meyer N, Mortier L, et al. Initial results from a phase 3b/4 study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511). Presented at: ESMO 2018 Congress; October 19-23, 2018; Munich, Germany. Abstract LBA47.
Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018. doi: 10.1016/S1470-2045(18)30700-9. [Epub ahead of print].
Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722-730.
Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672-681.
Hamid O, Robert C, Daud A, et al. 5-year survival outcomes in patients (pts) with advanced melanoma treated with pembrolizumab (pembro) in KEYNOTE-001. J Clin Oncol. 2018;36(suppl):Abstract 9516.
Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006. J Clin Oncol. 2018;36(suppl):Abstract 9503.
Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789-1801.
Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824-1835.
Weber J, Mandalà M, Del Vecchio M, et al. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). Presented at: 2018 ASCO® Annual Meeting; June 1-5, 2018; Chicago, IL. Abstract 9502.
Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813-1823.
Ribas A, Milhem M, Hoimes C, et al. Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. J Clin Oncol. 2018;36(suppl):Abstract 9513.
Diab A, Hurwitz M, Cho D, et al. NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: preliminary phase 1/2 results of PIVOT. Presented at: 2018 ASCO® Annual Meeting; June 1-5, 2018; Chicago, IL. Abstract 3006.
Diab A, Rahimian S, Haymaker C, et al. A phase 2 study to evaluate the safety and efficacy of Intratumoral (IT) injection of the TLR9 agonist IMO-2125 (IMO) in combination with ipilimumab (ipi) in PD-1 inhibitor refractory melanoma. J Clin Oncol. 2018;36(suppl):Abstract 9515.
Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell. 2017;170:1109-1119.e1110.
ClinicalTrials.gov. A phase 1b/3, multicenter, trial of talimogene laherparepvec in combination with pembrolizumab (MK-3475) for treatment of unresectable stage IIIB to IVM1c melanoma (MASTERKEY-265/KEYNOTE-034). https://clinicaltrials.gov/ct2/show/NCT02263508. Accessed October 29, 2018.
Madden K, Hoffner B. Ipilimumab-based therapy. Clin J Oncol Nurs. 2017;21(4 Suppl):30-41.
Brahmer JR, Lacchetti C, Schneider B, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714-1768.
Puzanov I, Diab A, Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95.
Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv142.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Management of immunotherapy-related toxicities. Version 1.2018.

CME / ABIM MOC / CE

From Adjuvant to Metastatic in Melanoma: What Should You Know?

Authors: Jeffrey S. Weber, MD, PhD; Richard D. Carvajal, MD; Douglas B. Johnson, MD
CME / ABIM MOC / CE Released: 12/24/2018
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/24/2019, 11:59 PM EST

Target Audience and Goal Statement

This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

The goal of this activity is to discuss the evolving role for immunotherapy in the treatment of patients with melanoma.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Clinical trial data on the use of cancer immunotherapies in the management of melanoma
Have greater competence related to
- Selecting the most appropriate regimen for patients with melanoma
- Collaborating with other members of the interprofessional team to produce optimal outcomes in the identification and management of immune-related adverse events

Moderator

Jeffrey S. Weber, MD, PhD

Professor of Medicine
Deputy Director
Laura and Isaac Perlmutter Cancer Center
NYU Langone Medical Center
New York, NY

Disclosures

Disclosure: Jeffrey S. Weber, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Altor BioScience; AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Celldex Therapeutics; CytomX Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Incyte Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Owns stock, stock options, or bonds from: Altor BioScience; Biond Biologics Ltd; CytomX Therapeutics, Inc.
Other: Named on a patent for a PD-1 biomarker by Biodesix, Inc.

Dr Weber does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Weber does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Richard D. Carvajal, MD

Associate Professor of Medicine
Columbia University Medical Center
Director
Experimental Therapeutics
Director
Melanoma Service
New York, NY

Disclosures

Disclosure: Richard D. Carvajal, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Aura Biosciences, Inc.; Bristol-Myers Squibb Company; Castle Biosciences, Inc.; Chimeron Bio; Foundation Medicine, Inc.; Genentech, Inc.; Immunocore; Incyte Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Rgenix; Roche

Dr Carvajal does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Carvajal does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Douglas B. Johnson, MD

Assistant Professor of Medicine
Vanderbilt University Medical Center
Director
Melanoma Program
Nashville, Tennessee

Disclosures

Disclosure: Douglas B. Johnson, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Array BioPharma; Bristol-Myers Squibb Company; Incyte Corporation; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation
Received grants for clinical research from: Bristol-Myers Squibb Company; Incyte Corporation

Dr Johnson does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Johnson does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Steering Committee

Jeffrey S. Weber, MD, PhD

Disclosures

As Above

Members

Robert L. Ferris, MD, PhD

Professor and Chief
Division of Head and Neck Surgery
Departments of Otolaryngology, Radiation Oncology, and Immunology
Co-Leader
Cancer Immunology Program
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Disclosures

Disclosure: Robert L. Ferris, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Benitec Bipharma Ltd; Bristol-Myers Squibb Company; EMD Serono, Inc.; Lilly; Merck & Co., Inc.; Pfizer Inc.; PPD; TESARO, Inc.
Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; MedImmune Inc.; Merck & Co., Inc.; TESARO, Inc.; VentiRx

Ramaswamy Govindan, MD

Professor of Medicine
Division of Medical Oncology
Washington University School of Medicine
Co-Director
Section of Medical Oncology
Siteman Cancer Center
Barnes-Jewish Hospital
St Louis, Missouri

Disclosures

Disclosure: Ramaswamy Govindan, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Adaptimmune; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; NeoHealth

Dung Le, MD

Associate Professor
Johns Hopkins University School of Medicine
Baltimore, Maryland
Participation by Dr Le does not constitute or imply endorsement by the Johns Hopkins University or the Johns Hopkins Hospital and Health System

Disclosures

Disclosure: Dung Le, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Merck & Co., Inc.
Served as a speaker or a member of a speakers bureau for: Merck & Co., Inc.
Received grants for clinical research from: Aduro Biotech; Bristol-Myers Squibb Company; Merck & Co., Inc.

Brian I. Rini, MD

Professor of Medicine
Lerner College of Medicine
Director
GU Program
Cleveland Clinic
Cleveland, Ohio

Disclosures

Disclosure: Brian I. Rini, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Merck & Co., Inc.; Pfizer Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; Merck & Co., Inc.; Pfizer Inc.

Jared Weiss, MD

Assistant Professor of Medicine
Lineberger Comprehensive Cancer Center
University of North Carolina at Chapel Hill

Disclosures

Disclosure: Jared Weiss, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Celgene Corporation; EMD Serono, Inc.; G1 Therapeutics; Immunicum; Nanobiotx; Regeneron Pharmaceuticals, Inc.
Received grants for clinical research from: Celgene Corporation; Merck & Co., Inc.; Pfizer Inc.

Editor

Charlotte Warren

Senior Scientific Director, Medscape, LLC

Disclosures

Disclosure: Charlotte Warren has disclosed no relevant financial relationships.

CME Reviewer

Esther Nyarko, PharmD

Associate Clinical CME Director, Medscape, LLC

Disclosures

Disclosure: Esther Nyarko, PharmD, has disclosed no relevant financial relationships.

Additional Planners

Kathleen M. Madden, NP

Nurse Practitioner
Laura and Isaac Perlmutter Cancer Center
NYU Langone Medical Center
New York, New York

Disclosures

Disclosure: Kathleen M. Madden, NP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant to: Merck & Co., Inc.

SITC Course Director

Paul Antony, MD

Assistant Professor
University of Maryland School of Medicine
Baltimore, Maryland

Disclosures

Disclosure: Paul Antony, MD, has disclosed no relevant financial relationships.

SITC

Claire Leischer, MS

Senior Manager of Online Education
Society for Immunotherapy of Cancer
Milwaukee, Wisconsin

Disclosures

Disclosure: Claire Leischer, MS, has disclosed no relevant financial relationships.

Alicia Schuessler, CAE

Director of Education
Society for Immunotherapy of Cancer
Milwaukee, Wisconsin

Disclosures

Disclosure: Alicia Schuessler, CAE, has disclosed no relevant financial relationships.

Tara Withington, CAE

Executive Director
Society for Immunotherapy of Cancer
Milwaukee, Wisconsin

Disclosures

Disclosure: Tara Withington has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and the Society for Immunotherapy of Cancer. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For Nurses

Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.50 contact hour(s) ( 0.050 CEUs) (Universal Activity Number: JA0007105-0000-18-303-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

From Adjuvant to Metastatic in Melanoma: What Should You Know?

Authors: Jeffrey S. Weber, MD, PhD; Richard D. Carvajal, MD; Douglas B. Johnson, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / ABIM MOC / CE Released: 12/24/2018

Valid for credit through: 12/24/2019, 11:59 PM EST

processing....

Educational Impact Challenge

The goal of this activity is to discuss the evolving role for immunotherapy in the treatment of patients with melanoma.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Society for Immunotherapy of Cancer

In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Society for Immunotherapy of Cancer. Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Jeffrey S. Weber, MD, PhD

Panelists

Richard D. Carvajal, MD

Douglas B. Johnson, MD

Steering Committee

Jeffrey S. Weber, MD, PhD

Members

Robert L. Ferris, MD, PhD

Ramaswamy Govindan, MD

Dung Le, MD

Brian I. Rini, MD

Jared Weiss, MD

Editor

Charlotte Warren

CME Reviewer

Esther Nyarko, PharmD

Additional Planners

Kathleen M. Madden, NP

SITC Course Director

Paul Antony, MD

SITC

Claire Leischer, MS

Alicia Schuessler, CAE

Tara Withington, CAE

Peer Reviewer

CME / ABIM MOC / CE

From Adjuvant to Metastatic in Melanoma: What Should You Know?

Target Audience and Goal Statement

Moderator

Jeffrey S. Weber, MD, PhD

Panelists

Richard D. Carvajal, MD

Douglas B. Johnson, MD

Steering Committee

Jeffrey S. Weber, MD, PhD

Members

Robert L. Ferris, MD, PhD

Ramaswamy Govindan, MD

Dung Le, MD

Brian I. Rini, MD

Jared Weiss, MD

Editor

Charlotte Warren

CME Reviewer

Esther Nyarko, PharmD

Additional Planners

Kathleen M. Madden, NP

SITC Course Director

Paul Antony, MD

SITC

Claire Leischer, MS

Alicia Schuessler, CAE

Tara Withington, CAE

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

From Adjuvant to Metastatic in Melanoma: What Should You Know?

Educational Impact Challenge